Obefazimod
-
Obefazimod Shows Anti-Fibrotic Potential and Enhanced Efficacy in IBD: New Data from ECCO 2026
Abivax presented significant findings on obefazimod at ECCO 2026, revealing its anti-fibrotic activity. Preclinical data demonstrated obefazimod’s potential to combat fibrosis, a key factor in IBD complications. This complements existing clinical data showing efficacy and a favorable safety profile in IBD patients. The dual focus on inflammation and fibrosis positions obefazimod as a potentially transformative therapy for a significant unmet need.
-
Abivax to Present Late-Breaking ABTECT Trial Results and Updated Safety Data
Abivax (ABVX) reported positive Phase 3 ABTECT trial results for obefazimod in ulcerative colitis. A pooled analysis showed a 16.4% placebo-adjusted clinical remission rate at Week 8 with the 50mg dose, meeting the FDA primary endpoint. Trials enrolled a refractory population, including patients who failed advanced therapies or JAK inhibitors. No new safety signals for serious infections or malignancies were reported. Headache and nausea were common adverse events. Analysts believe efficacy in the difficult-to-treat patient group could position obefazimod favorably in the market.
